CSIMarket Company Name, Ticker, Competitors, else..
 

Kazia Therapeutics Limited  (NASDAQ: KZIA)

Kazia Therapeutics Limited's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

KZIA Sales vs. its Competitors Q4 2025


Comparing the current results to its competitors, Kazia Therapeutics Limited reported Revenue decrease in the 4 quarter 2025 year on year by -98.31 %, despite the revenue increase by the most of its competitors of 78.57 %, recorded in the same quarter.

• List of KZIA Competitors





Revenue Growth Comparisons




Net Income Comparison

Kazia Therapeutics Limited, faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<<  KZIA Stock Performance Comparisons


Kazia Therapeutics Limited's Comment on Competition and Industry Peers


The company operates in a competitive environment that includes pharmaceutical and biotechnology firms, universities, and public and private research institutions developing products or drug candidates for similar therapeutic indications. Competitors may have products at more advanced development stages and may achieve commercialization earlier. The FDA may approve competing drugs if they demonstrate clinical superiority. Key competitive factors include efficacy, safety, side effects, price, market exclusivity, and healthcare regulations. The company's commercial opportunities may be limited if competitors develop treatments that are more effective, safer, or less costly.



  

Overall company Market Share Q4 2025
Overall company, revenue fell by -98.31 % and company lost market share, to approximately 0.01 %.




<<  More on KZIA Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Kazia Therapeutics Limited




Zymeworks Inc
Share Performance



-1.20%
This Year
Zymeworks Inc
Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,919.724 mill. $ 37.127 mill. $ -149.992 mill.


Oramed Pharmaceuticals Inc
Share Performance



+10.13%
30 Days
Oramed Pharmaceuticals Inc
Profile

Oramed Pharmaceuticals Inc. is a biopharmaceutical company with a business model focused on developing innovative oral drug delivery solutions.

More about Oramed Pharmaceuticals Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 199.858 mill. $ - mill. $ 174.864 mill.


Oncternal Therapeutics Inc
Share Performance



-89.68%
One Year
Oncternal Therapeutics Inc
Profile

Oncternal Therapeutics Inc's business model focuses on developing and commercializing novel therapies for the treatment of cancer.

More about Oncternal Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.220 mill. $ 2.161 mill. $ -34.575 mill.


Nextcure Inc
Share Performance



-8.32%
30 Days
Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 39.770 mill. $ - mill. $ -42.748 mill.


Nuvalent Inc
Share Performance



+48.63%
One Year
Nuvalent Inc
Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9,751.979 mill. $ - mill. $ -450.074 mill.

36 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Kazia Therapeutics Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kazia Therapeutics Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.